Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Mirabaud & Cie SA

Mirabaud & Cie SA raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 58,022 shares of the company’s stock after buying an additional 1,694 shares during the period. Moderna makes up about 0.8% of Mirabaud & Cie SA’s investment portfolio, making the stock its 27th largest holding. Mirabaud & Cie SA’s holdings in Moderna were worth $2,413,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of MRNA. Axiom Advisory LLC raised its position in shares of Moderna by 1.6% in the 3rd quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after acquiring an additional 198 shares during the period. Arkadios Wealth Advisors boosted its position in shares of Moderna by 2.2% during the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares in the last quarter. Knuff & Co LLC boosted its position in shares of Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after purchasing an additional 244 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Moderna by 7.9% in the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after buying an additional 245 shares during the period. Finally, Mather Group LLC. increased its position in shares of Moderna by 25.7% in the 3rd quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock valued at $86,000 after buying an additional 262 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Up 5.4 %

MRNA stock opened at $35.89 on Wednesday. The company has a fifty day moving average price of $40.68 and a two-hundred day moving average price of $65.48. Moderna, Inc. has a one year low of $31.94 and a one year high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.39) EPS. Equities analysts anticipate that Moderna, Inc. will post -9.27 earnings per share for the current year.

Insider Transactions at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. Company insiders own 15.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Barclays decreased their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. UBS Group lowered their target price on Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Sanford C. Bernstein initiated coverage on shares of Moderna in a research note on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Jefferies Financial Group lowered their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Finally, Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Four analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $75.58.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.